Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy
LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25 per cent weight loss.
Quartz on MSN15h
A new stronger Ozempic is coming. Here's what to knowNovo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...
Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...
Bloomberg L.P. on MSN9d
Novo Nordisk Shares Seen Outpacing Lilly’s After Summer StumbleNovo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity ...
It isn’t that Wall Street doubts the massive opportunity to treat hundreds of millions of people with obesity worldwide; ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback